Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online May 20, 2008
Diabetes Care 31:1496-1501, 2008
DOI: 10.2337/dc07-2334
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-2334v1
31/8/1496    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Skupien, J.
Right arrow Articles by Malecki, M. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skupien, J.
Right arrow Articles by Malecki, M. T.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Clinical Application of 1,5-Anhydroglucitol Measurements in Patients with Hepatocyte Nuclear Factor-1{alpha} Maturity-Onset Diabetes of the Young

Jan Skupien, MD, PHD1, Sylwia Gorczynska-Kosiorz, PHD2, Tomasz Klupa, MD, PHD1, Krzysztof Wanic, MD, PHD1, Eric A. Button, MS, MBA3, Jacek Sieradzki, MD, PHD1 and Maciej T. Malecki, MD, PHD1

1 Department of Metabolic Diseases, Jagiellonian University, Medical College, Krakow, Poland
2 Department of Internal Medicine, Diabetology and Nephrology, Silesian School of Medicine, Zabrze, Poland
3 BioMarker Group, Kannapolis, North Carolina

Corresponding author: Maciej T. Malecki, malecki_malecki{at}yahoo.com

OBJECTIVE—1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1{alpha} (HNF-1{alpha}) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1{alpha} MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1{alpha} MODY.

RESEARCH DESIGN AND METHODS—We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1{alpha} MODY.

RESULTS—The mean 1,5-AG plasma concentration in diabetic HNF-1{alpha} mutation carriers was 5.9 µg/ml, and it was lower than that in type 2 diabetic patients (11.0 µg/ml, P = 0.003) and in nondiabetic control subjects (23.9 µg/ml, P < 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1{alpha} MODY at the criterion of <6.5 µg/ml in patients with an A1C level between 6.5 and 9.0%.

CONCLUSIONS—1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1{alpha} MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1{alpha} mutation carriers for metabolic control has substantial limitations.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.